CELFULL’s introduction of Celfavor® NADH Microcapsules marks a significant breakthrough in anti-aging biotechnology, addressing the long-standing challenge of NADH instability that has hindered its clinical and therapeutic potential. Developed over a decade of research, this patented technology offers a unique microencapsulation system that protects NADH from degradation caused by heat, light, oxygen, and stomach acid. Backed by seven international invention patents and robust safety certifications, the innovation paves the way for reliable, shelf-stable delivery of one of the most powerful longevity molecules known to science.

What sets Celfavor® NADH apart is its AI-optimized microcapsule design, which ensures enhanced bioavailability, targeted intestinal release, and long-lasting stability without refrigeration. In human trials, it achieved a 98% increase in blood NAD⁺ levels—outperforming traditional NADH and other precursors like NMN and NR. The microcapsules sustain their efficacy under high temperature and humidity conditions for over six months and allow for co-formulation with vitamins, peptides, and other supplements. This positions the technology not only as a standalone solution but also as a foundation for next-generation multi-ingredient longevity formulations.

More than a product launch, CELFULL’s innovation reflects a broader mission to democratize access to anti-aging science. With the launch of its Global Research Sharing Program, CELFULL is offering free access to its Celfavor® NADH raw materials for scientific institutions worldwide, encouraging collaboration and accelerating breakthroughs in longevity research. As the anti-aging industry evolves into the “Microcapsule Age,” Celfavor® NADH stands at the forefront—delivering precision, performance, and purpose to redefine what’s possible in preventive health and human lifespan extension.